作者: Rory F. Finn
DOI: 10.1007/978-3-7643-8679-5_11
关键词:
摘要: Recombinant human growth hormone (hGH) is a well characterized molecule with broad acceptance as treatment for deficiencies (GHD). However, hGH requires daily injections due to the drug’s short duration of action. Many groups have focused on PEGylation means extend its half-life and generate less frequent dosage forms. This chapter provides review preclinical clinical results obtained from many approaches directed towards modification PEG. The will describe historical progression strategies results. first half discuss initial studies that utilized multiple 5 kDa PEG attachments extension subsequent development PEGylated receptor antagonist, pegvisomant, successful therapy acromegaly. latter summarize more recent current work focusing site selective mono-PEGylation hGH.